Trials / Completed
CompletedNCT02667288
An Open-Label Safety Study of A-101 Solution
An Open-Label Study of the Safety of A-101 Solution 40% in Subjects With Seborrheic Keratosis on the Trunk, Extremities and Face.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 147 (actual)
- Sponsor
- Aclaris Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label safety study. During this study, the investigator will identify 4 eligible SK Target Lesions on each subject on the trunk, extremities and face.
Detailed description
This is an open-label safety study. During this study, the investigator will identify 4 eligible SK Target Lesions on each subject on the trunk, extremities and face. The Target Lesions will be treated a maximum of 4 times.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | A-101 Solution |
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2016-10-01
- Completion
- 2016-10-01
- First posted
- 2016-01-28
- Last updated
- 2018-02-07
- Results posted
- 2017-11-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02667288. Inclusion in this directory is not an endorsement.